Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

332.13 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Is NASDAQ:PODD a Fit for high Growth Investing Strategies?
Is INSULET CORP (NASDAQ:PODD) suited for high growth investing? 
Via Chartmill
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Insulet Corporation
Via Business Wire
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today
 
Via Benzinga
Analyst Expectations For Insulet's Future
 
Via Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
 
Via Benzinga
(PODD) - Analyzing Insulet's Short Interest
 
Via Benzinga
Upstart, Insulet And 2 Other Stocks Executives Are Selling
 
Via Benzinga
Affirm, Mongodb And Best Buy Are Among Top 10 Large Cap Gainers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
Top-performing large-cap stocks from last week: AFRM, NTNX, MDB, BBY, GEV, TCOM, COO, PODD, VEEV, AZPN. 
Via Benzinga
Why Insulet Stock Was Zooming Higher This Week
The company had encouraging news to impart about its leading insulin pump. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Insulet Stock In The Last 10 Years
 
Via Benzinga
Stocks To Watch Today: PODD, SMCI, And PAYC
Insulet Corporation surged on FDA approval for its diabetes treatment device, while SMCI faced pressure from a short-seller report, and Paycom Software saw insider selling activity. 
Via Talk Markets
The Latest Analyst Ratings For Insulet
 
Via Benzinga
Peering Into Insulet's Recent Short Interest
 
Via Benzinga
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
From Insulet Corporation
Via Business Wire
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the latest. 
Via Benzinga
Topics Stocks
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Here's How Much $100 Invested In Insulet 10 Years Ago Would Be Worth Today
 
Via Benzinga
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
Stocks On Track For Weekly Losses Despite Midday Gains
The Dow Jones Industrial Average, Nasdaq Composite, and S&P 500 Index are attempting to pare this morning's losses as they move into positive territory for the afternoon. 
Via Talk Markets
Topics Stocks
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulet reported a Q2 adjusted EPS of $0.55, slightly missing estimates but showing strong sales growth of 23.2% year-over-year, driven by Omnipod revenue. The company raised its 2024 revenue guidance,... 
Via Benzinga
PODD Stock Earnings: Insulet Misses EPS, Beats Revenue for Q2 2024
PODD stock results show that Insulet missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims... 
Via Benzinga
Topics Economy Stocks
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the... 
Via Benzinga
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
Why Is Omnipod Insulin Device Maker Insulet Stock Jumping Today?
Insulet Corporation shares are rising after the company reported stronger-than-expected second-quarter revenue, driven by high demand for Omnipod 5 and a raised full-year revenue outlook. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.